Acute effects of renin-angiotensin system blockade on arterial function in hypertensive patients

Effects of Antihypertensive Drugs on Central Blood Pressure in Humans: A Preliminary Observation

“…16 Dihydropyridine calcium channel blockers and angiotensin II receptor blockers are expected to reduce both central and peripheral BP, [17][18][19][20][21][22][23] and our results confirm this finding. Diuretic compounds were considered to have little or no effect on central BP, 24,25 particularly when thiazide agents were used, in small clinical trials.…”

Diurnal variation of endothelial function and arterial stiffness in hypertension

“…This finding might extend the concept of chronotherapy of hypertension to further target diurnal changes of vascular function 43 as some antihypertensive drugs also improve endothelial function and arterial stiffness. [30][31][32] Whether drug-induced effects on the circadian rhythm of blood pressure 44 are followed by similar effects on the arterial stiffness temporal pattern is not known. 45 Further study is needed to investigate the mechanisms involved in this phenomenon and to address its implications in our understanding of the circadian variation in cardiovascular events.…”

“…Identification of the variation of these markers, which are related with increased cardiovascular risk in hypertensive patients particularly at early stages of hypertension, could be useful in their management as some antihypertensive drugs may also improve endothelial function and arterial stiffening. [30][31][32] Furthermore, it could offer an insight to the mechanisms responsible for the temporal variation of cardiovascular events. We hypothesized that the circadian variation of endothelial function and arterial stiffness is preserved in newly diagnosed hypertensives at relatively low cardiovascular risk.…”

Effect of Angiotensin Receptor Blockers on Flow-Mediated Vasodilation: A Meta-Analysis of Randomized Controlled Trials

“…We excluded 14 trials because endothelial function was not evaluated by brachial FMD (n = 9) [43,44,45,46,47,48,49,50,51] or because FMD data were not available at baseline or at the end of treatment (n = 5; fig. 1) [52,53,54,55,56]. Among the 26 trials remaining in the present meta-analysis, 9 had a crossover design [16,17,18,22,24,27,28,32,40] and 17 had a parallel design [19,20,21,23,25,26,29,30,31,33,34,35,36,37,38,39,41]; 11 had a placebo-controlled design [17,18,19,22,24,25,27,28,31,35,38], 13 had an active drug-controlled design [16,20,21,23,26,29,30,33,34,36,39,40,41], and 2 had both of them [32,37].…”

“…We restricted our search spectrum to full-text articles written in English or Chinese language, and articles performed in human subjects. We identified 40 trials [16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,43,44,45,46,47,48,49,50,51,52,53,54,55,56] published between 1999 and 2013. We excluded 14 trials because endothelial function was not evaluated by brachial FMD (n = 9) [43,44,45,46,47,48,49,50,51] or because FMD data were not available at baseline or at the end of treatment (n = 5; fig.…”